GSK And Pfizer RSV Vaccines Get US Recommendation – But Big Decisions On Pricing Yet To Come

GSK and Pfizer have both raised their price ranges based on longer-term efficacy data for their RSV vaccines, but Pfizer may choose to undercut on price in order to win market share against its rival’s more favorable data.